NCT01702714撤回1 期
A MULTICENTER, OPEN-LABEL PHASE IB STUDY OF RO5083945 IN COMBINATION WITH CISPLATIN AND GEMCITABINE OR CARBOPLATIN AND PACLITAXEL IN PATIENTS WITH ADVANCED OR RECURRENT NON SMALL CELL LUNG CANCER OF SQUAMOUS HISTOLOGY WHO HAVE NOT RECEIVED PRIOR CHEMOTHERAPY FOR THE METASTATIC DISEASE.
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 主要终点
- Maximum tolerated dose in combination with cisplatin and gemcitabine or carboplatin and paclitaxel
研究概览
简要总结
This open-label, multicenter, non-randomized, dose-escalating phase Ib study with an expansion cohort will determine the recommended Phase II dose and schedule to investigate safety, tolerability, and activity of RO5083945 in combination with cisplatin and gemcitabine or carboplatin and paclitaxel in patients with advanced or recurrent non-small cell lung cancer of squamous histology who have not received prior chemotherapy for the metastatic disease. Cohorts of patients will receive escalating doses of RO5083945 in combination with up to 6 cycles of cisplatin and gemcitabine or carboplatin and paclitaxel. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult patients, >/= 18 years of age
- •Locally advanced (stage IIIB, excluding patients who are candidates for chemo-radiotherapy or radical thoracic radiotherapy), metastatic (stage IV) or recurrent squamous non-small cell lung cancer (NSCLC)
- •Histologically documented squamous NSCLC. Mixed tumors should be categorized according to the predominant cell type
- •Histological tumor tissue sample from initial diagnosis or new tumor biopsy representative of the disease
- •Patients who have received adjuvant chemotherapy are eligible if the last administration of the prior adjuvant regimen occurred at least 3 months prior to enrollment
- •At least one measurable disease lesion as per RECIST 1.1 criteria
- •Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- •Adequate hematological, liver and renal function
- •Females of childbearing potential must commit to using a reliable and appropriate method of contraception until at least 3 months after the end of the last dose of study treatment
排除标准
- •Prior chemotherapy (excluding neoadjuvant/adjuvant chemotherapy/chemo-radiotherapy) or treatment with another systemic anti-cancer agent (e.g. monoclonal antibody, tyrosine kinase inhibitor)
- •Radiotherapy within the last 4 weeks prior to first dosing, except for limited field palliative radiotherapy for bone pain relief
- •Treatment with any other investigational agent within 30 days prior to starting study treatment or participation in another clinical trial (e.g. CTC blood collection) within 7 days prior to starting study treatment
- •Historical or clinical evidence of central nervous system (CNS) metastases (except for previously treated CNS metastases in patients that are asymptomatic, have had no evidence of active CNS metastases for >/= 3 months prior to first dose and have had no requirement for steroids or enzyme-inducing anticonvulsants in the last 14 days)
- •Recent history of poorly controlled hypertension (systolic >180 mmHg or diastolic >100 mmHg)
- •Severe uncontrolled illness, including poorly controlled diabetes mellitus and active or uncontrolled infection
- •Hypersensitivity to the active substance or to any excipients or to any of the study drugs including premedication (corticosteroids, anti-histamine, paracetamol)
- •Pregnant or breastfeeding women
研究组 & 干预措施
RO5083945 + carboplatin + paclitaxel
Experimental
干预措施: RO5083945 (Drug)
RO5083945 + carboplatin + paclitaxel
Experimental
干预措施: carboplatin (Drug)
RO5083945 + carboplatin + paclitaxel
Experimental
干预措施: paclitaxel (Drug)
RO5083945 + cisplatin +gemcitabine
Experimental
干预措施: RO5083945 (Drug)
RO5083945 + cisplatin +gemcitabine
Experimental
干预措施: cisplatin (Drug)
RO5083945 + cisplatin +gemcitabine
Experimental
干预措施: gemcitabine (Drug)
结局指标
主要结局
Maximum tolerated dose in combination with cisplatin and gemcitabine or carboplatin and paclitaxel
时间窗: approximately 1.5 years
Recommended phase II dose (RP2D) of RO5083945 in combination with cisplatin and gemcitabine or carboplatin and paclitaxel
时间窗: approximately 1.5 years
次要结局
- Biomarker assessments : Immune effector cells/EGFR markers(up to 18 weeks)
- Safety: Incidence of adverse events(approximately 1.5 years)
- Pharmacokinetics: Serum concentrations of RO5083945 in combination with cisplatin and gemcitabine or carboplatin and paclitaxel(up to 18 weeks)
- Pharmacokinetics: Effect of RO5083945 on serum concentrations of cisplatin(up to 18 weeks)
- Pharmacokinetics: Effect of RO5083945 on serum concentrations of gemcitabine(up to 18 weeks)
- Pharmacokinetics: Effect of RO5083945 on serum concentrations of carboplatin(up to 18 weeks)
- Pharmacokinetics: Effect of RO5083945 on serum concentrations of paclitaxel(up to 18 weeks)
- Preliminary evidence of antitumor activity: Objective response rate (complete response, partial response and stable disease)(approximately 1.5 years)
- Duration of response(approximately 1.5 years)
研究者
相似试验
已完成
1 期
A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid TumorsSolid TumorsNCT02650713Hoffmann-La Roche228
已完成
1 期
KN046 in Subjects With Advanced Solid Tumors and LymphomaAdvanced Solid TumorsLymphomaNCT03733951Jiangsu Alphamab Biopharmaceuticals Co., Ltd139
招募中
1 期
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Ductal AdenocarcinomaBorderline Resectable Pancreatic AdenocarcinomaLocally Advanced Pancreatic AdenocarcinomaPancreatic CancerNCT06673017PanTher Therapeutics26
已完成
1 期
A Study of CS1003 in Subjects With Advanced Solid Tumors or LymphomasSolid TumorLymphomaNCT03809767CStone Pharmaceuticals107
已完成
1 期
A Phase Ia/Ib Study of CS1001 in Subjects With Advanced Solid TumorsAdvanced CancerNCT03312842CStone Pharmaceuticals259